These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 8678066)

  • 21. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients.
    Kalantar-Zadeh K; McAllister CJ; Lehn RS; Lee GH; Nissenson AR; Kopple JD
    Am J Kidney Dis; 2003 Oct; 42(4):761-73. PubMed ID: 14520627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Erythropoietin and transfusions in patients with anemia of chronic renal failure origin : an update view].
    Duclos J; Olea C; Aguirre H; Alvarez MC; Salgado MC
    Rev Med Chil; 1995 Apr; 123(4):451-5. PubMed ID: 8525189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoietin response to blood loss in hemodialysis patients in blunted but preserved.
    Ross RP; McCrea JB; Besarab A
    ASAIO J; 1994; 40(3):M880-5. PubMed ID: 8555638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States.
    Obrador GT; Ruthazer R; Arora P; Kausz AT; Pereira BJ
    J Am Soc Nephrol; 1999 Aug; 10(8):1793-800. PubMed ID: 10446948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of periodic transfusion on erythropoietin concentration in end stage renal disease.
    Hong SY; Yang DH
    Korean J Intern Med; 1992 Jul; 7(2):122-9. PubMed ID: 1306073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erythropoietin treatment improves quality of life in hemodialysis patients.
    Bárány P; Pettersson E; Bergström J
    Scand J Urol Nephrol Suppl; 1990; 131():55-60. PubMed ID: 2075471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does the use of erythropoietin in hemodialysis patients increase dialysis graft thrombosis rates?
    Standage BA; Schuman ES; Ackerman D; Gross GF; Ragsdale JW
    Am J Surg; 1993 May; 165(5):650-4. PubMed ID: 8488954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.
    Cody J; Daly C; Campbell M; Donaldson C; Grant A; Khan I; Pennington S; Vale L; Wallace S; MacLeod A
    Cochrane Database Syst Rev; 2001; (4):CD003266. PubMed ID: 11687180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In patients treated with peritoneal dialysis, icodextrin improves erythropoietin-resistant anemia through blockade of asialo receptors on hepatocytes.
    Adachi Y; Nakagawa Y; Nishio A
    Adv Perit Dial; 2006; 22():41-4. PubMed ID: 16983937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythropoietin requirements increase following hospitalization in end-stage renal disease patients.
    Yaqub MS; Leiser J; Molitoris BA
    Am J Nephrol; 2001; 21(5):390-6. PubMed ID: 11684801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis.
    Shrivastava D; Rao TK; Sinert R; Khurana E; Lundin AP; Friedman EA
    Am J Kidney Dis; 1995 Jun; 25(6):904-9. PubMed ID: 7771487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resurgence of blood transfusion therapy in erythropoietin treated hemodialysis patients.
    Ifudu O; Macey LJ; Friedman EA
    ASAIO J; 1995; 41(3):M426-30. PubMed ID: 8573839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonalcoholic fatty liver disease (NAFLD)--is it a new marker of hyporesponsiveness to recombinant human erythropoietin in patients that are on chronic hemodialysis?
    Orlic L; Mikolasevic I; Lukenda V; Racki S; Stimac D; Milic S
    Med Hypotheses; 2014 Dec; 83(6):798-801. PubMed ID: 25456789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary hyperthyroidism induced erythropoietin-resistant anemia?
    Jyo-Oshiro Y; Nomura S; Fukushima T; Tamai H; Fueki H; Osawa G
    Intern Med; 1997 Dec; 36(12):903-5. PubMed ID: 9475248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Past, present and future of erythropoietin use in the elderly.
    de Francisco AL; Fernandez Fresnedo G; Rodrigo E; Piñera C; Heras M; Palomar R; Ruiz JC; Arias M
    Int Urol Nephrol; 2002; 33(1):187-93. PubMed ID: 12090329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study.
    Albertazzi A; Di Liberato L; Daniele F; Battistel V; Colombi L
    Int J Artif Organs; 1998 Jan; 21(1):12-8. PubMed ID: 9554820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.